The First Hospital Affiliated to Xiamen University
Welcome,         Profile    Billing    Logout  
 13 Trials 
12 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Xiaoying
NCT05816057: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

Completed
3
476
RoW
semaglutide injection
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Diabetes Mellitus, Type 2
07/23
10/23
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
NCT05834868: Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

Recruiting
3
805
RoW
THDB0206 Injection, Insulin Lispro Injection
Tonghua Dongbao Pharmaceutical Co.,Ltd
Type 2 Diabetes
03/24
10/24
NCT06396429: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Recruiting
3
540
RoW
HRS9531 injection, Placebo
Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight or Obesity
07/25
08/25
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Active, not recruiting
3
623
RoW
Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin
Hangzhou Sciwind Biosciences Co., Ltd.
T2DM, Type 2 Diabetes Mellitus
10/24
10/24
NCT05702073: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.

Recruiting
3
400
RoW
INS068 injection, Insulin Glargine
Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
10/24
10/24
NCT05881837: Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Active, not recruiting
2
249
RoW
HRS9531 injection, HRS9531 injection Placebo
Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight or Obesity
10/24
10/24
HDM1002-201, NCT06500299: Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Not yet recruiting
2
180
NA
HDM1002 100 mg QD, HDM1002, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks, Placebo
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight and Obesity
10/24
11/24
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
NCT05516966: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

Completed
1
64
RoW
HRS9531, Placebo, Dulaglutide Injection
Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
05/23
05/23
NCT06520540: HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

Not yet recruiting
1
72
RoW
HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks,Q 2W for titration, HDM1002 400 mg QD 12weeks,Q 3W for titration, Placebo
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Glucagon-Like Peptide-1 Receptor Agonists
11/24
12/24
NCT06427642: Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Recruiting
N/A
120
RoW
Mononuclear cells, Mild hypothermia therapy, Breathing support technique, Total parenteral nutrition
Shandong Qilu Stem Cells Engineering Co., Ltd., Qilu Children's Hospital of Shandong University
Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, Short Bowel Syndrome
05/24
04/25

Download Options